Copanlisib (BAY80-6946)

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Conditions

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Trial Timeline

Jul 1, 2022 โ†’ Aug 31, 2024

About Copanlisib (BAY80-6946)

Copanlisib (BAY80-6946) is a pre-clinical stage product being developed by Bayer for Relapsed or Refractory Indolent Non-Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05217914. Target conditions include Relapsed or Refractory Indolent Non-Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (5)

NCT IDPhaseStatus
NCT05217914Pre-clinicalCompleted
NCT02455297Phase 2Terminated
NCT02342665Phase 1/2Completed
NCT02155582Phase 1Completed
NCT02119221Phase 1Completed

Competing Products

20 competing products in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

See all competitors